ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B
11 Giugno 2019 - 2:30PM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development of therapeutic drugs for the
treatment of liver disease arising from non-alcoholic
steatohepatitis (“NASH”) and chronic viral infection, today
announced that the peer-reviewed journal, PLOS ONE, has published
ContraVir’s research article entitled “The Cyclophilin Inhibitor
CRV431 Inhibits Liver HBV DNA and HBsAg in Transgenic Mice.”
“The research article reports our discovery that
CRV431 greatly reduces HBV DNA in the liver of transgenic mice in a
dose-dependent manner,” said Dr. Robert Foster, Chief Executive
Officer of ContraVir. “CRV431 interferes with the way that HBV
hijacks our body’s molecules to amplify virus replication, which is
distinct from traditional antiviral drugs such as tenofovir that
bind only to HBV proteins. Additionally, CRV431 reduced serum
levels of HBsAg, an important prognostic indicator, which is
typically not decreased by nucleotide drugs. This study suggests
that CRV431 and tenofovir can be used in combination to
significantly decrease HBV DNA levels in the liver, and we are
conducting further studies to elucidate CRV431’s mechanism of
action.”
The article describes a study where Hepatitis B
virus (“HBV”) transgenic mice were treated with CRV431, a
cyclophilin inhibitor; and/or tenofovir exalidex (“TXL”), a
nucleotide prodrug. Mice were treated daily for a period of 16 days
receiving either 10 mg/kg of CRV431; 50 mg/kg of CRV431; 5 mg/kg of
TXL; 10 mg/kg of TXL; a combination of 10 mg/kg of CRV431 and 5
mg/kg of TXL; or vehicle control. Key findings of the study
include:
- CRV431 decreased liver HBV DNA
levels dose-dependently, where the low (10 mg/kg/day) and high (50
mg/kg/day) doses of CRV431 reduced HBV DNA levels by 13% and 91%,
respectively, compared to the vehicle group.
- TXL also decreased liver HBV DNA
levels dose-dependently, where the low (5 mg/kg/day) and high (10
mg/kg/day) doses of TXL reduced HBV DNA levels by 55% and 97%,
respectively, compared to the vehicle group.
- In mice that were co-dosed with the
lowest tested doses of CRV431 (10 mg/kg/day) and TXL (5 mg/kg/day),
liver HBV DNA decreased by 80% compared to the vehicle group.
The article may be accessed at:
https://doi.org/10.1371/journal.pone.0217433.
About ContraVir
Pharmaceuticals
ContraVir is a clinical stage biopharmaceutical
company focused on the development of targeted therapies for liver
disease arising from non-alcoholic steatohepatitis (NASH) and
chronic hepatitis virus infection (HBV, HCV, HDV). The company’s
lead drug candidate, CRV431, reduces liver fibrosis and
hepatocellular carcinoma tumor burden in experimental models of
NASH. Preclinical studies also have demonstrated antiviral
activities towards HBV, HCV, and HDV through several mechanisms.
These diverse therapeutic activities result from CRV431’s potent
inhibition of cyclophilin enzymes, which are involved in many
disease processes. Currently in clinical phase development, CRV431
shows potential to play an important role in the overall treatment
of liver disease - from triggering events through to end-stage
disease. For more information, please
visit www.contravir.com.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be
identified by the use of forward-looking words such as
“anticipate,” “believe,” “forecast,” “estimated,” and “intend,”
among others. These forward-looking statements are based on
ContraVir’s current expectations and actual results could differ
materially. There are a number of factors that could cause
actual events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir
does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in ContraVir’s Form 10-K for the year ended December 31,
2018 and other periodic reports filed with the Securities and
Exchange Commission.
For further information, please contact:
Stephen KilmerContraVir Investor Relations(646)
274-3580skilmer@contravir.com
Grafico Azioni Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Storico
Da Giu 2023 a Giu 2024